Figure 4
From: Upregulated expression of FGF13/FHF2 mediates resistance to platinum drugs in cervical cancer cells
Expression of FGF13 protein in biopsy samples of cervical cancers from patients who received chemoradiotherapy using cisplatin.
The subjects were 20 patients with cervical cancer. All patients received conventional chemoradiotherapy consisting of five weekly administrations of cisplatin (40 mg/m2). They also received radiotherapy (30.6 Gy) to the whole pelvis plus additional parametric radiation with central shielding to complete a 50.6 Gy dose, along with 192Ir high dose-rate intracavitary brachytherapy. Levels of FGF13 expression were analyzed using a streptavidin-biotin immunoperoxidase technique. Negative controls for all experiments (no primary antibody) were incubated in the same manner at each step. For each biopsy sample, 10 non-overlapping fields were randomly selected and analyzed and the percentage of cells positive for FGF13 expression per total tumor cells in each field was calculated. A. Representative immunohistochemical staining of FGF13 for comparison with prognosis. Positive cell counts are expressed as the average number of cells per field. B. Percentages of FGF13-positive cells. *, p < 0.05. If two extreme results are omitted from each group, p value becomes 0.02.
